Athletes with mild COVID-19 illness demonstrate subtle imaging abnormalities without exercise impairment or arrhythmias

Ben T. Costello1†, Rachel E. Climie1,2†, Leah Wright1, Kristel Janssens1, Amy Mitchell1, Imogen Wallace1, Anniina Lindqvist1, Steve Foulkes1, Elizabeth D. Paratz1, Michael D. Flannery1, Nicholas Saner1, David Griffin3, Danny J. Green4, Brian Cowie1, Erin H. Howden1, Andrew Garnham5, and Andre La Gerche 1,6*

1Sports Cardiology Lab, Baker Heart and Diabetes Institute, Level 4, 99 Commercial Rd, Melbourne, VIC 3004, Australia; 2Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool Street, Hobart, TAS 7000, Australia; 3Infectious Disease Department, Alfred Hospital, Commercial Road, Melbourne, VIC 3004, Australia; 4School of Human Sciences, University of Western Australia, 35 Stirling Highway, Perth 6009, Australia; 5Faculty of Health, Deakin University, 221 Burwood Highway, Burwood, VIC 3125, Australia; and 6National Centre for Sports Cardiology, St Vincent’s Hospital Melbourne, Victoria Parade, Fitzroy, VIC 3065, VIC, Australia

Coronavirus disease-19 (COVID-19) has been associated with cardiac pathology raising the possibility of serious cardiac arrhythmias among athletes returning to competition post infection.1–3 Several studies have assessed cardiac function and structure in athletes post-COVID-19 infection but have been challenged by selection bias, lack of an appropriate control group and none have included comprehensive imaging, exercise testing, and clinical electrophysiology.2,4–7

We recruited every player from a squad of professional basketballers involved in a ‘super-spreader’ event that lead to a majority being infected with COVID-19 following a single training session in Melbourne, Australia. We compared those athletes who tested positive to COVID-19 by polymerase chain reaction diagnostic testing (16 athletes) to athletes who (i) tested negative and (ii) had no symptoms suggestive of COVID-19 infection (n = 8).

Our hypothesis was that electrocardiogram, biochemical, and imaging variants are common in highly trained athletes and would not be more prevalent in athletes recovering from COVID-19 than non-infected teammates.

Comprehensive testing was performed between 10 and 21 days from the time of testing positive to COVID-19. Testing involved clinical assessment, biochemistry (including cardiac troponin I and B-type natriuretic peptide), 12-lead electrocardiography, 24-h Holter monitoring, cardiopulmonary exercise testing, echocardiography, studies of flow mediated dilation, and cardiac magnetic resonance imaging (CMR). Regional myocardial fibrosis was visually identified by delayed gadolinium enhancement (DGE), T1 mapping was analysed using a mid-wall region of the septum and three T2 measurements were analysed; mid septum, global left ventricle, and the highest T2 time at any site. A comprehensive description of all methods is included as supplementary content.

COVID-19 positive athletes had mild (75%) or moderate (25%) symptoms including ageusia/anosmia, fevers, myalgias, and cough persisting for a maximum of 6 days. One COVID-19 positive athlete had a known history of hypertrophic cardiomyopathy and one had been evaluated for ventricular ectopics several years prior.

COVID-19 positive athletes were similar in age, gender, biochemical markers of cardiac damage, exercise capacity, and ventilatory efficiency when compared with COVID-19 negative athletes. Similarly, there were no differences in electrocardiographic measures, arrhythmias, or ventricular pauses, nor any differences in cardiac or vascular imaging markers (see Table 1). Of note, one COVID-19 positive athlete with hypertrophic cardiomyopathy had a mildly elevated troponin, infero-lateral T-wave inversion, and minor DGE. One other COVID-19 positive athlete had evidence of DGE comprising a very small patch in the mid lateral wall (athlete 6 in Figure 1) and one COVID-19 negative athlete had very small patches of mid septal enhancement (athlete 3 Figure 1). In both cases the troponin, T1 and T2 mapping were normal and there were no arrhythmias on a 24-h Holter study. Native, post-contrast and T2 mapping were not different between groups. Pericardial enhancement and/or trivial pericardial effusions were frequently observed and were equally represented between groups (see Figure 1). Apart from the athlete

* Corresponding author. Tel: +61 (0)3 8532 1899, Email: andre.lagerche@baker.edu.au
† The first two authors contributed equally to the manuscript.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.
|                      | COVID +ve athletes (n = 16) | COVID −ve athletes (n = 8) | P-value |
|----------------------|-----------------------------|---------------------------|---------|
| **Demographics**     |                             |                           |         |
| Age (years)          | 25 ± 6                      | 27 ± 5                    | 0.45    |
| Sex, male, n (%)     | 12 (75)                     | 6 (75)                    | 1.0     |
| Height (m)           | 1.92 ± 0.14                 | 1.87 ± 0.11               | 0.35    |
| Weight (kg)          | 84 ± 13                     | 84 ± 16                   | 0.99    |
| Body mass index (kg/m²) | 22.76 ± 2.40              | 23.80 ± 2.05              | 0.29    |
| **Biochemistry**     |                             |                           |         |
| Haemoglobin (g/L)    | 145 ± 12                    | 146 ± 12                  | 0.89    |
| B-type natriuretic peptide (pg/mL) | 18 ± 23               | 8 ± 4                     | 0.089   |
| Cardiac Troponin I (ng/L) | 25 ± 54               | 21 ± 51                   | 0.85    |
| Elevated troponin (>14ng/L) | 3                   | 1                         | 0.70    |
| **Cardiopulmonary exercise test** |                   |                           |         |
| Peak exercise heart rate (b.p.m.) | 185 ± 9               | 187 ± 15                  | 0.83    |
| Peak respiratory exchange ratio | 1.3 ± 0.9             | 1.3 ± 0.4                 | 0.18    |
| Peak VO₂ (L/min)     | 3.60 ± 0.71                 | 3.91 ± 0.92               | 0.42    |
| Peak VO₂ (mL/kg/min) | 41.5 ± 5.0                  | 47.2 ± 10.6               | 0.18    |
| **Electrocardiogram** |                             |                           |         |
| Heart rate (b.p.m.)  | 56 ± 9                      | 54 ± 11                   | 0.69    |
| QTc-interval (ms)    | 386 ± 61                    | 398 ± 16                  | 0.46    |
| Abnormal T-wave inversion | 1                        | 0                         | 0.67    |
| Left bundle branch block | 0                        | 0                         | 1.0     |
| 24-h Holter monitor  |                             |                           |         |
| Pauses >2 s          | 2.3 ± 6.8                   | 2.9 ± 5.5                 | 0.81    |
| Ventricular ectopics over 24 h | 92 ± 344              | 20 ± 55                   | 0.43    |
| Non-sustained VT     | 0                           | 0                         | 1.0     |
| Number supraventricular beats | 11 ± 14                  | 31 ± 37                   | 0.18    |
| Number of AT or AF episodes | 0                        | 0                         | 1.0     |
| **Cardiac magnetic resonance imaging** |                   |                           |         |
| LVEDV/BSA (mL/m²)    | 100 ± 16                    | 110 ± 11                  | 0.10    |
| LVESV/BSA (mL/m²)    | 43 ± 11                     | 45 ± 7                    | 0.71    |
| LVEF (%)             | 58 ± 3                      | 59 ± 5                    | 0.66    |
| LV mass/BSA (g/m²)   | 76 ± 9                      | 83 ± 5                    | 0.020   |
| RVEDV/BSA (mL/m²)    | 111 ± 15                    | 124 ± 10                  | 0.27    |
| RVEF (%)             | 50 ± 3                      | 51 ± 7                    | 0.72    |
| LAVI (mL/m²)         | 35 ± 11                     | 35 ± 7                    | 0.95    |
| RA area (cm²)        | 24 ± 5                      | 26 ± 4                    | 0.51    |
| Native T1 (ShMOLLI, ms) | 1134 ± 38                | 1142 ± 32                 | 0.59    |
| ECV (%)              | 25 ± 3                      | 24 ± 3                    | 0.96    |
| T2 (ms)—septum      | 37.6 ± 1.8                  | 37.5 ± 2.0                | 0.87    |
| T2 (ms)—mid SAX     | 38.4 ± 1.7                  | 38.5 ± 1.9                | 0.92    |
| T2 (ms)—max segment | 42.6 ± 4.7                  | 42.2 ± 2.7                | 0.79    |
| Pericardial enhancement ± effusion | 4                        | 6                         | 0.44    |
| DGE                  | 2                           | 1                         | 0.72    |
| **Echocardiography** |                             |                           |         |
| Global longitudinal strain (%) | −17.4 ± 2.6           | −19.1 ± 2.0               | 0.094   |
| Mechanical dispersion (ms) | 39 ± 5                | 37 ± 6                    | 0.53    |
| Mitral valve E/A     | 2.2 ± 0.9                   | 2.2 ± 0.8                 | 0.86    |
| TDI E’ septal (cm/s) | 11.7 ± 2.6                  | 12.1 ± 2.3                | 0.68    |
| E/e’ septal          | 6 ± 2                       | 6 ± 1                     | 0.93    |
| TR max pressure (mmHg) | 19 ± 1                  | 18 ± 2                    | 0.80    |

Continued
|                           | COVID +ve athletes (n = 16) | COVID −ve athletes (n = 8) | P-value |
|---------------------------|----------------------------|----------------------------|---------|
| Flow-mediated dilation    |                            |                            |         |
| Resting diameter (cm)    | 0.44 ± 0.6                 | 0.44 ± 0.5                 | 0.82    |
| Peak diameter (cm)       | 0.47 ± 0.06                | 0.48 ± 0.05                | 0.57    |
| Flow-mediated dilation (%)| 6.5 ± 2.8                  | 8.4 ± 2.8                  | 0.14    |
| Shear stimulus SR (auc)  | 13428 ± 7377               | 9195 ± 5907                | 0.15    |

AF, atrial fibrillation; AT, atrial tachycardia; DGE, delayed gadolinium enhancement; ECV, extracellular matrix; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; LAVI, left atrial volume indexed; LV, left ventricle; LVH, left ventricular hypertrophy; RA, right atrium; RV, right ventricle; STIR, short tau inversion recovery; TDI, tissue Doppler Imaging, DT; TR, tricuspid regurgitation; VCO2, volume of carbon dioxide produced; VE, ventilation volume; VO2, volume of oxygen uptake; VT, ventricular tachycardia.

**Figure 1** Delayed enhancement of the myocardium and pericardium in athletes with and without prior COVID-19 infection. Long-axis phase sensitive inversion recovery (PSIR) images after gadolinium demonstrating very small patches of myocardial enhancement (royal blue arrows) and pericardial enhancement (light blue arrowheads) in four athletes with and without COVID.
with hypertrophic cardiomyopathy, very minor elevations in troponin were observed in three additional athletes (two COVID-19 positive and one COVID-19 negative, \( P = 0.70 \)). In these athletes, there were no other abnormalities on imaging or exercise testing. At 6-month post-assessment, all athletes continue training and competition without any symptoms or clinical events.

With the goal of assessing the health outcomes in professional athletes returning to sport after COVID-19 infection, this cohort study is unique in the completeness of selection and the comprehensiveness of the measures. By enrolling all athletes from a single team at the start of a pandemic outbreak (with extremely low chance of prior infection), it was possible to eliminate selection bias. Prior studies may have been compromised by a tendency to recruit athletes with symptoms sufficient to warrant testing. Furthermore, the comparison with appropriate control athletes provides important qualification of the assumption that all abnormalities in COVID-19 athletes are significant. For example, troponin elevations are considered pathological in most settings, but abnormalities in COVID-19 athletes are significant. For example, troponin elevations are considered pathological in most settings, but abnormalities in COVID-19 athletes are significant.

Similarly, the finding of ventricular ectopics, increases in CMR mapping values or pericardial abnormalities may have been considered significant if it were not for the comparison with an appropriate control group.

Studies to date have tended to focus on cardiac imaging abnormalities without the context of impact on symptoms, exercise capacity, or electrophysiological abnormalities. In comparing athletes with mild COVID-19 illness to a group of uninfected athletes, we observed no differences in imaging parameters and a lack of association with abnormalities on biochemistry, exercise testing or electrophysiology. The findings from these detailed examinations add to the reassurance provided from larger but less comprehensive studies of athletes recovering from COVID-19 illness.

In conclusion, abnormalities can be observed in athletes’ biomarkers, imaging, and electrophysiology, regardless of COVID-19 infection. These are not associated with persisting symptoms, exercise intolerance, or clinical sequelae.

Conflict of interest: none declared.

Data availability statement
The data underlying this article will be shared on reasonable request to the corresponding author.

References
1. Puntmann VO, Carej ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Schendrygina A, Escher F, Vasa-Nicotera M, Zeiher AM, Vehreschild M, Nagel E. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265.
2. Brito D, Meester S, Yanamala N, Patel HB, Balick BJ, Casacang-Verzosa G, Seetharam K, Riveros D, Brito RJ 2nd, Balla S, Morseau A, J, Sengupta PP. High prevalence of pericardial involvement in college student athletes recovering from COVID-19. JACC Cardiovasc Imaging 2021;14:541–555.
3. Bhatia RT, Marwaha S, Malhotra A, Iqbal Z, Hughes C, Börjesson M, Niebauer J, Pelliccia A, Schmied C, Serratosa L, Papadakis M, Sharma S. Exercise in the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) era: a question and answer session with the experts endorsed by the section of Sports Cardiology & Exercise of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2020;27:1242–1251.
4. Martinez MW, Tucker AM, Bloom OJ, Green G, DiFiori JP, Solomon G, Phelan D, Kim JH, Meeuwisse W, Silas AK, Rowe D, Bogoch II, Smith PT, Baggish AL, Putukian M, Engel D. Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening. JAMA Cardiol 2021;6:745.
5. Rajpal S, Tong MS, Borchers J, Zareba KM, Obarski TP, Simonetti OP, Daniels CJ. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol 2021;6:116–118.
6. Mousson N, Petek BJ, Drezen JA, Harmon KG, Kliehthemas SA, Patel MR, Baggish AL. Outcomes Registry for Cardiac Conditions in Athletes. Conditions in Athletes Investigators. SARS-CoV-2 cardiac involvement in young competitive athletes. Circulation 2021;144:256–266.
7. Starekova J, Bluemke DA, Bradham WS, Eckhardt LL, Grist TM, Kusmirek JE, Purtell CS, Schiebler ML, Reeder SB. Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging. JAMA Cardiol 2021;6:945.
8. Lopez-Lual J, Legaz-Arrese A, George K, Serveto-Galindo O, Gonzalez-Rave JM, Reverter-Masia J, Munguia-Izquierdo D. Cardiac troponin I release after a basketball match in elite, amateur and junior players. Clin Chem Lab Med 2016;54:333–338.
9. Phelan D, Kim JH, Elliott MD, Wasyf MR, Cremer P, John AM, Emeery MS, Sengupta PP, Sharma S, Martinez MW, La Gerche A. Screening of potential cardiac involvement in competitive athletes recovering from COVID-19: an expert consensus statement. JACC Cardiovasc Imaging 2020;13:2635–2652.